Clinical trials: Breast Cancer, Metastatic Breast Cancer
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Metastatic Breast Cancer, Response Monitoring
FDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
Several studies have shown improved sensitivity of FDG-PET/CT compared with conventional imaging for diagnosing metastatic breast cancer in retrospective and smaller prospective studies.
- Trial name
- MONITOR-RCT (NCT06877949)
- Testing
- FDG-PET/CT, CE-CT
- Where
- 11 sites in Denmark, Germany and 1 more
- Volunteers
- 420 people
- Sponsor
- Odense University Hospital
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Breast Neoplasms, Lung Neoplasms
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
TROPION-DM/BrUOG-431 is a prospective, , phase 2 trial with two non-comparative cohorts analyzed jointly for primary endpoint in adult patients with either (Cohort 1:) advanced/metastatic hormone-receptor positive ([HR+]…
- Trial name
- NCT06974604
- Testing
- Dexamethasone oral
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Brown University
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER I (NCT00305448)
- Testing
- Fulvestrant
- Where
- 35 sites in Japan
- Volunteers
- 143 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
One important approach to change the natural history of advanced breast cancer is that of designing new combination chemotherapies in which the best drugs already available are used together with new anticancer agents devoid of…
- Trial name
- NCT00367250
- Testing
- Cetuximab, Trastuzumab
- Where
- Austria
- Volunteers
- 32 people
- Sponsor
- Medical University of Vienna
Breast Cancer
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00834678
- Testing
- bendamustine, erlotinib, Maintenance erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breast Cancer
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
SOLTI 1903 HOPE is a national, real world clinical practice study conducted in patients diagnosed with metastatic breast cancer who are receiving, have just received or will receive treatment for its advanced disease.
- Trial name
- HOPE (NCT04497285)
- Testing
- blood sample collection and collection of tumor tissue block
- Where
- Spain
- Volunteers
- 600 people
- Sponsor
- SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.
- Trial name
- NCT01654185
- Testing
- AI plus Dimethyldiguanide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xichun Hu
Chemotherapy, Breast Cancer, Metastatic
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature.
- Trial name
- NCT01067989
- Testing
- Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- HaEmek Medical Center, Israel
Breast Cancer
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.
- Trial name
- NCT00193180
- Testing
- Imatinib, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer, Brain Metastasis
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
The incidence of brain metastases (BM) in metastatic breast cancer is increasing, due to the improvement in the control of systemic disease, and due to an improved detection through imagery.
- Trial name
- NCT01942980
- Testing
- Radiation therapy Brain metastasis in breast cancer
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer Metastatic, Breast Cancer Stage IV
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the…
- Trial name
- SAFIR3LibHERty (NCT06680596)
- Testing
- trastuzumab derxutecan
- Where
- 40 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER
Breast Cancer
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.
- Trial name
- NCT00095706
- Testing
- Bevacizumab (drug), Herceptin (drug)
- Where
- 18 sites in United States
- Volunteers
- 50 people
- Sponsor
- Translational Oncology Research International
Breast Cancer
Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Disitamab Vedotin (RC48) contains the novel humanized anti-HER2 antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable linker , which is the first ADC drug that was independently developed by Rongchang Biology .The…
- Trial name
- NCT06000033
- Testing
- Disitamab Vedotin+Anlotinib
- Volunteers
- 35 people
- Sponsor
- Qilu Hospital of Shandong University
Breast Cancer
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin together versus eribulin alone, in participants with locally recurrent or metastatic breast cancer.
- Trial name
- NCT01427933
- Testing
- Ramucirumab (IMC-1121B), Eribulin
- Where
- 52 sites in United States
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls…
- Trial name
- NCT01990352
- Testing
- Pegylated liposomal doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
HER2-low Breast Cancer
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
This is a multicenter, single-arm, phase II clinical trial designed to evaluate the efficacy and safety of disitamab vedotin in combination with bevacizumab in patients with HER2-low advanced or metastatic breast cancer who have…
- Trial name
- NCT07446452
- Testing
- Disitamab Vedotin (RC48), Bevacizumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Metastatic Breast Cancer
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to…
- Trial name
- KORNELIA (NCT04061863)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.